Browse SRPK1

Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 2: Cytoplasm. Nucleus. Nucleus matrix. Microsome. Note=Shuttles between the nucleus and the cytoplasm. Inhibition of the Hsp90 ATPase activity, osmotic stress and interaction with HHV-1 ICP27 protein can induce its translocation to the nucleus. KAT5/TIP60 inhibits its nuclear translocation.; SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Nucleus matrix. Microsome. Note=Mainly localized in the microsomal fraction and the cytoplasm, and to a lesser extent in the nuclear matrix.
Domain PF00069 Protein kinase domain
Function

Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing. Plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. Can influence additional steps of mRNA maturation, as well as other cellular activities, such as chromatin reorganization in somatic and sperm cells and cell cycle progression. Isoform 2 phosphorylates SFRS2, ZRSR2, LBR and PRM1. Isoform 2 phosphorylates SRSF1 using a directional (C-terminal to N-terminal) and a dual-track mechanism incorporating both processive phosphorylation (in which the kinase stays attached to the substrate after each round of phosphorylation) and distributive phosphorylation steps (in which the kinase and substrate dissociate after each phosphorylation event). The RS domain of SRSF1 binds first to a docking groove in the large lobe of the kinase domain of SRPK1. This induces certain structural changes in SRPK1 and/or RRM2 domain of SRSF1, allowing RRM2 to bind the kinase and initiate phosphorylation. The cycles continue for several phosphorylation steps in a processive manner (steps 1-8) until the last few phosphorylation steps (approximately steps 9-12). During that time, a mechanical stress induces the unfolding of the beta-4 motif in RRM2, which then docks at the docking groove of SRPK1. This also signals RRM2 to begin to dissociate, which facilitates SRSF1 dissociation after phosphorylation is completed. Isoform 2 can mediate hepatitis B virus (HBV) core protein phosphorylation. It plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles. Isoform 1 and isoform 2 can induce splicing of exon 10 in MAPT/TAU. The ratio of isoform 1/isoform 2 plays a decisive role in determining cell fate in K-562 leukaemic cell line: isoform 2 favors proliferation where as isoform 1 favors differentiation.

> Gene Ontology
 
Biological Process GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000398 mRNA splicing, via spliceosome
GO:0006323 DNA packaging
GO:0006397 mRNA processing
GO:0006997 nucleus organization
GO:0007059 chromosome segregation
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007286 spermatid development
GO:0007289 spermatid nucleus differentiation
GO:0008380 RNA splicing
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0035092 sperm chromatin condensation
GO:0043484 regulation of RNA splicing
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045069 regulation of viral genome replication
GO:0045070 positive regulation of viral genome replication
GO:0045071 negative regulation of viral genome replication
GO:0048024 regulation of mRNA splicing, via spliceosome
GO:0048232 male gamete generation
GO:0048515 spermatid differentiation
GO:0048524 positive regulation of viral process
GO:0048525 negative regulation of viral process
GO:0050684 regulation of mRNA processing
GO:0050792 regulation of viral process
GO:0071103 DNA conformation change
GO:1903311 regulation of mRNA metabolic process
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0000287 magnesium ion binding
GO:0004674 protein serine/threonine kinase activity
Cellular Component GO:0016363 nuclear matrix
GO:0034399 nuclear periphery
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SRPK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SRPK1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 3.74; FDR: 0.046 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SRPK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.20.513
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2080.903
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.190.886
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3560.244
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2950.885
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4330.868
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0190.961
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0030.999
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0860.964
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2010.863
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3390.836
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1670.0307
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SRPK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRPK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRPK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRPK1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRPK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SRPK1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SRPK1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSRPK1
NameSRSF protein kinase 1
Aliases SFRSK1; SR protein kinase 1; serine/arginine-rich splicing factor kinase 1; SFRS protein kinase 1; SR-protei ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SRPK1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.